Trials / Not Yet Recruiting
Not Yet RecruitingNCT06241469
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction (CZTU-1)：a Phase II Clinical Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Wu Jun · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to find better protocal for adenocarcinoma of the gastric and gastroesophageal juncion. The main question is aim to answer is: 1\. The efficacy and safety of PD-1 monoclonal antibody (Sintilimab) combined with nab-paclitaxel and S-1 in the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Participants will be given PD-1 monoclonal antibody, nab-paclitaxel and tegio.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab,nab-paclitaxel and tegio | Immunotherapy combined with chemotherapy |
Timeline
- Start date
- 2024-02-03
- Primary completion
- 2026-08-02
- Completion
- 2027-02-02
- First posted
- 2024-02-05
- Last updated
- 2024-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06241469. Inclusion in this directory is not an endorsement.